1887

Abstract

The glucocorticoid betamethasone (BM) is frequently employed in clinical practice because of its anti-inflammatory and immunosuppressive properties. In this study, we investigated the effect of BM (1 and 2 mM) on the ability of to adhere to, invade and damage oral, intestinal or vaginal epithelial cells, as well as to elicit cytokine and chemokine release. BM at 2 mM concentration stimulated adherence of to vaginal cells and facilitated the invasion of intestinal and vaginal epithelia without influencing the growth rate of invading hyphae at any type of epithelia and BM concentrations tested. In addition, BM at 2 mM concentration also augmented -initiated cell damage of oral and intestinal cells. Furthermore, BM exposure decreased IL-6 cytokine and IL-8 chemokine release from oral and vaginal epithelial cells and also IL-6 release from intestinal epithelium after infection with . These observations suggest that high-dose applications of BM may predispose patients to various epithelial infections.

Loading

Article metrics loading...

/content/journal/micro/10.1099/mic.0.000383
2016-12-21
2019-12-15
Loading full text...

Full text loading...

/deliver/fulltext/micro/162/12/2116.html?itemId=/content/journal/micro/10.1099/mic.0.000383&mimeType=html&fmt=ahah

References

  1. Abraham S. M., Clark A. R.. 2006; Dual-specificity phosphatase 1: a critical regulator of innate immune responses. Biochem Soc Trans34:1018–1023 [CrossRef][PubMed]
    [Google Scholar]
  2. Akpan A., Morgan R.. 2002; Oral candidiasis. Postgrad Med J78:455–459 [CrossRef][PubMed]
    [Google Scholar]
  3. Ashman R. B., Papadimitriou J. M.. 1995; Production and function of cytokines in natural and acquired immunity to Candida albicans infection. Microbiol Rev59:646–672[PubMed]
    [Google Scholar]
  4. Bodey G. P., Mardani M., Hanna H. A., Boktour M., Abbas J., Girgawy E., Hachem R. Y., Kontoyiannis D. P., Raad I. I.. 2002; The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med112:380–385 [CrossRef][PubMed]
    [Google Scholar]
  5. Botas C. M., Kurlat I., Young S. M., Sola A.. 1995; Disseminated candidal infections and intravenous hydrocortisone in preterm infants. Pediatrics95:883–887[PubMed]
    [Google Scholar]
  6. Bykov V. L.. 1989; Morphological analysis of the effect of corticosteroids on the development and course of vaginal candidiasis. Akush Ginekol2:35–37
    [Google Scholar]
  7. Calderone R. A.. 2002; Candida and Candidiasis Washington, DC: ASM Press;
    [Google Scholar]
  8. Calderone R. A., Fonzi W. A.. 2001; Virulence factors of Candida albicans. Trends Microbiol9:327–335 [CrossRef][PubMed]
    [Google Scholar]
  9. Dalle F., Wächtler B., L'Ollivier C., Holland G., Bannert N., Wilson D., Labruère C., Bonnin A., Hube B.. 2010; Cellular interactions of Candida albicans with human oral epithelial cells and enterocytes. Cell Microbiol12:248–271 [CrossRef][PubMed]
    [Google Scholar]
  10. Falgier C., Kegley S., Podgorski H., Heisel T., Storey K., Bendel C. M., Gale C. A.. 2011; Candida species differ in their interactions with immature human gastrointestinal epithelial cells. Pediatr Res69:384–389 [CrossRef][PubMed]
    [Google Scholar]
  11. Farkas G., Márton J., Mándi Y., Leindler L.. 2006; Surgical management and complex treatment of infected pancreatic necrosis: 18-year experience at a single center. J Gastrointest Surg10:278–285 [CrossRef][PubMed]
    [Google Scholar]
  12. Giard D. J., Aaronson S. A., Todaro G. J., Arnstein P., Kersey J. H., Dosik H., Parks W. P.. 1973; In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst51:1417–1423[PubMed]
    [Google Scholar]
  13. Golebski K., van Egmond D., de Groot E. J., Roschmann K. I., Fokkens W. J., van Drunen C. M.. 2015; EGR-1 and DUSP-1 are important negative regulators of pro-allergic responses in airway epithelium. Mol Immunol65:43–50 [CrossRef][PubMed]
    [Google Scholar]
  14. Gyetvai A., Emri T., Fekete A., Varga Z., Gazdag Z., Pesti M., Belágyi J., Emõdy L., Pócsi I., Lenkey B.. 2007; High-dose methylprednisolone influences the physiology and virulence of Candida albicans ambiguously and enhances the candidacidal activity of the polyene antibiotic amphotericin B and the superoxide-generating agent menadione. FEMS Yeast Res7:265–275 [CrossRef][PubMed]
    [Google Scholar]
  15. Höfs S., Mogavero S., Hube B.. 2016; Interaction of Candida albicans with host cells: virulence factors, host defense, escape strategies, and the microbiota. J Microbiol54:149–169 [CrossRef][PubMed]
    [Google Scholar]
  16. Hovi L., Saarinen-Pihkala U. M., Vettenranta K., Saxen H.. 2000; Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years. Bone Marrow Transplant26:999–1004 [CrossRef][PubMed]
    [Google Scholar]
  17. Jakab Á., Emri T., Sipos L., Kiss Á., Kovács R., Dombrádi V., Kemény-Beke Á., Balla J., Majoros L., Pócsi I.. 2015; Betamethasone augments the antifungal effect of menadione—towards a novel anti-Candida albicans combination therapy. J Basic Microbiol55:973–981 [CrossRef][PubMed]
    [Google Scholar]
  18. Jayatilake J. A., Samaranayake L. P., Lu Q., Jin L. J.. 2007; IL-1alpha, IL-1ra and IL-8 are differentially induced by Candida in experimental oral candidiasis. Oral Dis13:426–433 [CrossRef][PubMed]
    [Google Scholar]
  19. Karkowska-Kuleta J., Rapala-Kozik M., Kozik A.. 2009; Fungi pathogenic to humans: molecular bases of virulence of Candida albicans, Cryptococcus neoformans and Aspergillus fumigatus. Acta Biochim Pol56:211–224[PubMed]
    [Google Scholar]
  20. Koh A. Y.. 2013; Murine models of Candida gastrointestinal colonization and dissemination. Eukaryot Cell 12:1416–1422[CrossRef]
    [Google Scholar]
  21. Kudo T., Aoyagi Y., Fujii T., Ohtsuka Y., Nagata S., Shimizu T.. 2010; Development of Candida albicans colitis in a child undergoing steroid therapy for ulcerative colitis. J Pediatr Gastroenterol Nutr51:96–99 [CrossRef][PubMed]
    [Google Scholar]
  22. Lionakis M. S., Kontoyiannis D. P.. 2003; Glucocorticoids and invasive fungal infections. Lancet362:1828–1838 [CrossRef][PubMed]
    [Google Scholar]
  23. Maraki S., Hajiioannou I., Anatoliotakis N., Plataki M., Chatzinikolaou I., Zoras O., Tselentis Y., Samonis G.. 1999; Ceftriaxone and dexamethasone affecting yeast gut flora in experimental mice. J Chemother11:363–366 [CrossRef][PubMed]
    [Google Scholar]
  24. Mavor A. L., Thewes S., Hube B.. 2005; Systemic fungal infections caused by Candida species: epidemiology, infection process and virulence attributes. Curr Drug Targets6:863–874 [CrossRef][PubMed]
    [Google Scholar]
  25. Mayer F. L., Wilson D., Hube B.. 2013; Candida albicans pathogenicity mechanisms. Virulence4:119–128 [CrossRef][PubMed]
    [Google Scholar]
  26. Meyer J. E., Harder J., Görögh T., Weise J. B., Schubert S., Janssen D., Maune S.. 2004; Human beta-defensin-2 in oral cancer with opportunistic Candida infection. Anticancer Res24:1025–1030[PubMed]
    [Google Scholar]
  27. Mostefaoui Y., Bart C., Frenette M., Rouabhia M.. 2004; Candida albicans and Streptococcus salivarius modulate IL-6, IL-8, and TNF-alpha expression and secretion by engineered human oral mucosa cells. Cell Microbiol6:1085–1096 [CrossRef][PubMed]
    [Google Scholar]
  28. Moyes D. L., Naglik J. R.. 2011; Mucosal immunity and Candida albicans infection. Clin Dev Immunol2011:346307 [CrossRef][PubMed]
    [Google Scholar]
  29. Moyes D. L., Richardson J. P., Naglik J. R.. 2015; Candida albicans–epithelial interactions and pathogenicity mechanisms: scratching the surface. Virulence6:338–346 [CrossRef][PubMed]
    [Google Scholar]
  30. Moyes D. L., Wilson D., Richardson J. P., Mogavero S., Tang S. X., Wernecke J., Höfs S., Gratacap R. L., Robbins J. et al. 2016; Candidalysin is a fungal peptide toxin critical for mucosal infection. Nature532:64–68 [CrossRef][PubMed]
    [Google Scholar]
  31. Murzyn A., Krasowska A., Augustyniak D., Majkowska-Skrobek G., Łukaszewicz M., Dziadkowiec D.. 2010; The effect of Saccharomyces boulardii on Candida albicans-infected human intestinal cell lines Caco-2 and intestin 407. FEMS Microbiol Lett310:17–23 [CrossRef][PubMed]
    [Google Scholar]
  32. Myerowitz R. L.. 1981; Gastrointestinal and disseminated candidiasis. An experimental model in the immunosuppressed rat. Arch Pathol Lab Med105:138–143[PubMed]
    [Google Scholar]
  33. Naglik J. R., Moyes D. L., Wächtler B., Hube B.. 2011; Candida albicans interactions with epithelial cells and mucosal immunity. Microbes Infect13:963–976 [CrossRef][PubMed]
    [Google Scholar]
  34. Odds F. C.. 1987; Candida infections: an overview. Crit Rev Microbiol15:1–5 [CrossRef][PubMed]
    [Google Scholar]
  35. Pande K., Chen C., Noble S. M.. 2013; Passage through the mammalian gut triggers a phenotypic switch that promotes Candida albicans commensalism. Nat Genet45:1088–1091 [CrossRef][PubMed]
    [Google Scholar]
  36. Patterson J. E.. 1999; Epidemiology of fungal infections in solid organ transplant patients. Transpl Infect Dis1:229–236 [CrossRef][PubMed]
    [Google Scholar]
  37. Perlroth J., Choi B., Spellberg B.. 2007; Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med Mycol45:321–346 [CrossRef][PubMed]
    [Google Scholar]
  38. Polke M., Hube B., Jacobsen I. D.. 2015; Candida survival strategies. Adv Appl Microbiol91:139–235 [CrossRef][PubMed]
    [Google Scholar]
  39. Pryor B. D., Bologna S. G., Kahl L. E.. 1996; Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum39:1475–1482 [CrossRef][PubMed]
    [Google Scholar]
  40. Rovin B. H., Tang Y., Sun J., Nagaraja H. N., Hackshaw K. V., Gray L., Rice R., Birmingham D. J., Yu C. Y. et al. 2005; Clinical significance of fever in the systemic lupus erythematosus patient receiving steroid therapy. Kidney Int68:747–759 [CrossRef][PubMed]
    [Google Scholar]
  41. Saegusa S., Totsuka M., Kaminogawa S., Hosoi T.. 2007; Cytokine responses of intestinal epithelial-like Caco-2 cells to non-pathogenic and opportunistic pathogenic yeasts in the presence of butyric acid. Biosci Biotechnol Biochem71:2428–2434 [CrossRef][PubMed]
    [Google Scholar]
  42. Sardi J. C., Scorzoni L., Bernardi T., Fusco-Almeida A. M., Mendes Giannini M. J.. 2013; Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol62:10–24 [CrossRef][PubMed]
    [Google Scholar]
  43. Schäcke H., Döcke W. D., Asadullah K.. 2002; Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther96:23–43 [CrossRef][PubMed]
    [Google Scholar]
  44. Schaller M., Boeld U., Oberbauer S., Hamm G., Hube B., Korting H. C.. 2004; Polymorphonuclear leukocytes (PMNs) induce protective Th1-type cytokine epithelial responses in an in vitro model of oral candidosis. Microbiology150:2807–2813 [CrossRef][PubMed]
    [Google Scholar]
  45. Steele C., Fidel P. L.. 2002; Cytokine and chemokine production by human oral and vaginal epithelial cells in response to Candida albicans. Infect Immun70:577–583 [CrossRef][PubMed]
    [Google Scholar]
  46. Sudbery P. E.. 2011; Growth of Candida albicans hyphae. Nat Rev Microbiol9:737–748 [CrossRef][PubMed]
    [Google Scholar]
  47. Sudbery P., Gow N., Berman J.. 2004; The distinct morphogenic states of Candida albicans. Trends Microbiol12:317–324 [CrossRef][PubMed]
    [Google Scholar]
  48. Sung J. M., Ko W. C., Huang J. J.. 2001; Candidaemia in patients with dialysis-dependent acute renal failure: aetiology, predisposing and prognostic factors. Nephrol Dial Transplant16:2348–2356 [CrossRef][PubMed]
    [Google Scholar]
  49. Villar C. C., Kashleva H., Mitchell A. P., Dongari-Bagtzoglou A.. 2005; Invasive phenotype of Candida albicans affects the host proinflammatory response to infection. Infect Immun73:4588–4595 [CrossRef][PubMed]
    [Google Scholar]
  50. Wächtler B., Wilson D., Haedicke K., Dalle F., Hube B.. 2011a; From attachment to damage: defined genes of Candida albicans mediate adhesion, invasion and damage during Interaction with oral epithelial cells. PLoS One6:e17046 [CrossRef]
    [Google Scholar]
  51. Wächtler B., Wilson D., Hube B.. 2011b; Candida albicans adhesion to and invasion and damage of vaginal epithelial cells: stage-specific inhibition by clotrimazole and bifonazole. Antimicrob Agents Chemother55:4436–4439 [CrossRef][PubMed]
    [Google Scholar]
  52. Webb B. C., Thomas C. J., Willcox M. D., Harty D. W., Knox K. W.. 1998; Candida-associated denture stomatitis. Aetiology and management: a review. Part 3. Treatment of oral candidosis. Aust Dent J43:244–249 [CrossRef][PubMed]
    [Google Scholar]
  53. Wilson D., Hebecker B., Moyes D. L., Miramón P., Jablonowski N., Wisgott S., Allert S., Naglik J. R., Hube B.. 2013; Clotrimazole dampens vaginal inflammation and neutrophil infiltration in response to Candida albicans infection. Antimicrob Agents Chemother57:5178–5180 [CrossRef][PubMed]
    [Google Scholar]
  54. Yapar N.. 2014; Epidemiology and risk factors for invasive candidiasis. Ther Clin Risk Manag10:95–105 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/micro/10.1099/mic.0.000383
Loading
/content/journal/micro/10.1099/mic.0.000383
Loading

Data & Media loading...

Supplements

Supplementary File 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error